Evidence map›Paper›PMID 25945005›Full record

ArticleWorld journal of gastroenterology2015

Proton-pump inhibitors for prevention of upper gastrointestinal bleeding in patients undergoing dialysis.

Young Rim Song, Hyung Jik Kim, Jwa-Kyung Kim, Sung Gyun Kim, Sung Eun Kim

Open access · hybridAbstract read
In one paragraph

Article in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. The Mortality Risk of Proton Pump Inhibitors in 1.9 Million US Seniors: An Extended Cox Survival Analysis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022
    Trial
  2. Gastrointestinal disease in end-stage renal disease.World journal of nephrology · 2025
    Review
  3. Article
  4. Review
  5. Observational
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Young Rim SongYoung Rim Song, Hyung Jik Kim, Jwa-Kyung Kim, Sung Gyun Kim, Division of Nephrology, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Kidney Research Institute, Hallym University College of Medicine, Anyang-si 431-070, South Korea.
Hyung Jik KimYoung Rim Song, Hyung Jik Kim, Jwa-Kyung Kim, Sung Gyun Kim, Division of Nephrology, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Kidney Research Institute, Hallym University College of Medicine, Anyang-si 431-070, South Korea.
Jwa-Kyung KimYoung Rim Song, Hyung Jik Kim, Jwa-Kyung Kim, Sung Gyun Kim, Division of Nephrology, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Kidney Research Institute, Hallym University College of Medicine, Anyang-si 431-070, South Korea.
Sung Gyun KimYoung Rim Song, Hyung Jik Kim, Jwa-Kyung Kim, Sung Gyun Kim, Division of Nephrology, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Kidney Research Institute, Hallym University College of Medicine, Anyang-si 431-070, South Korea.
Sung Eun KimYoung Rim Song, Hyung Jik Kim, Jwa-Kyung Kim, Sung Gyun Kim, Division of Nephrology, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Kidney Research Institute, Hallym University College of Medicine, Anyang-si 431-070, South Korea.
Hallym University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo investigate the preventive effects of low-dose proton-pump inhibitors (PPIs) for upper gastrointestinal bleeding (UGIB) in end-stage renal disease.

methodsThis was a retrospective cohort study that reviewed 544 patients with end-stage renal disease who started dialysis at our center between 2005 and 2013. We examined the incidence of UGIB in 175 patients treated with low-dose PPIs and 369 patients not treated with PPIs (control group).

resultsDuring the study period, 41 patients developed UGIB, a rate of 14.4/1000 person-years. The mean time between the start of dialysis and UGIB events was 26.3 ± 29.6 mo. Bleeding occurred in only two patients in the PPI group (2.5/1000 person-years) and in 39 patients in the control group (19.2/1000 person-years). Kaplan-Meier analysis of cumulative non-bleeding survival showed that the probability of UGIB was significantly lower in the PPI group than in the control group (log-rank test, P < 0.001). Univariate analysis showed that coronary artery disease, PPI use, anti-coagulation, and anti-platelet therapy were associated with UGIB. After adjustments for the potential factors influencing risk of UGIB, PPI use was shown to be significantly beneficial in reducing UGIB compared to the control group (HR = 13.7, 95%CI: 1.8-101.6; P = 0.011).

conclusionThe use of low-dose PPIs in patients with end-stage renal disease is associated with a low frequency of UGIB.

Indexed as

Renal DialysisAgedDisease-Free SurvivalFemaleGastrointestinal HemorrhageHumansIncidenceKaplan-Meier EstimateKidney Failure, ChronicMaleMiddle AgedProton Pump InhibitorsRepublic of KoreaRetrospective StudiesRisk FactorsTime FactorsProton Pump InhibitorsDialysisEnd-stage renal diseaseGastrointestinal hemorrhagePeptic ulcerProton pump inhibitors

Identifiers

PMID25945005
PMCPMC4408464
OpenAlexW2057898517

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.